Bcal Diagnostics (ASX:BDX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Bcal Diagnostics (ASX:BDX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
BCAL to Acquire Shares in Genetic Signatures
BCAL acquires 10.2% stake in Genetic Signatures to expand diagnostics portfolio
BCAL Secures Funding for FY2027
BCAL Diagnostics secures $4.9 million funding and $1.4 million R&D tax offset for FY2027
BCAL Develops New Blood Test for Breast Cancer Recurrence
BCAL develops blood test BREASTEST Monitor for detecting local breast cancer recurrence
Validation Agreement Signed with Sonic USA, for Breastest V2
BCAL Launches Early Detection Cancer Platform
BCAL Diagnostics expands early cancer test access via GP software, telehealth launch, and new clinic
BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
BCAL Diagnostics names Anne-Louise Arnett as new CEO to drive commercial growth
Quarterly Activities/Appendix 4C Cash Flow Report
BCAL Diagnostics launches national Avantect tests, advances BREASTESTplus 2.0, seeks Medicare reimbursement
